ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.77 USD
-0.22 (-1.16%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $18.76 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACAD 18.77 -0.22(-1.16%)
Will ACAD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
Other News for ACAD
Needham healthcare analysts hold analyst/industry conference call
Needham healthcare analysts hold analyst/industry conference call
Oppenheimer Remains a Hold on ACADIA Pharmaceuticals (ACAD)
Needham healthcare analysts hold analyst/industry conference call
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024